Roche set to walk away from $6.8 billion Illumina bid

Wed Apr 18, 2012 2:54pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

By Caroline Copley and Soyoung Kim

ZURICH/NEW YORK (Reuters) - Swiss drugmaker Roche ROG.VX said on Wednesday it would not extend a $6.8 billion hostile offer for genetic specialist Illumina (ILMN.O: Quote) as the U.S. group's shareholders blocked its move to appoint new directors.

Roche, which is now set to walk away from its takeover target, said an offer above $51.00 per share would not be in the interests of its own shareholders.

The tender offer for Illumina expires on Friday and Roche said it would not extend the bid as the U.S. firm's management had refused to engage in constructive dialogue.

The decision is a victory for Illumina in its battle to stay independent, although some investors think Roche may wait in the wings for a fresh opportunity to pounce if the U.S. company's shares underperform.

The gene sequencing specialist, which branded itself "the Apple (AAPL.O: Quote) of the genomics business", rejected Roche's sweetened takeover offer and had repeatedly urged shareholders to vote against appointing Roche's nominees to its board.

"It won't hurt Roche to send a signal that they can walk away from these deals," said Navid Malik, an analyst at Cenkos Securities.

Roche, the world's largest maker of cancer drugs, has been developing targeted therapies and Illumina's technology would help it to progress further in this field as gene sequencing can better identify which patients benefit from a given drug.

But there are also other approaches Roche can take, given its existing strong position in diagnostics.   Continued...

 
The logo of Swiss pharmaceutical company Roche is seen at the company's headquarters in Basel April 5, 2012. REUTERS/Arnd Wiegmann